We are analyzing https://link.springer.com/article/10.1186/s12929-016-0305-9.

Title:
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors | Journal of Biomedical Science
Description:
The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (1/2G EGFR-TKIs) gefitinib, erlotinib, and afatinib have all been approved as standard first-line treatments for advanced EGFR mutation-positive non-small cell lung cancer. The third-generation (3G) EGFR-TKIs have been developed to overcome the EGFR T790M mutation, which is the most common mechanism of acquired resistance to 1/2G EGFR-TKI treatment. This resistance mutation develops in half of the patients who respond to 1/2G EGFR-TKI therapy. The structures of the novel 3G EGFR-TKIs are different from those of 1/2G EGFR-TKIs. Particularly, 3G EGFR-TKIs have lower affinity to wild-type EGFR, and are therefore associated with lower rates of skin and gastrointestinal toxicities. However, many of the adverse events (AEs) that are observed in patients receiving 3G EGFR-TKIs have not been observed in patients receiving 1/2G EGFR-TKIs. Although preclinical studies have revealed many possible mechanisms for these AEs, the causes of some AEs remain unknown. Many mechanisms of resistance to 3G EGFR-TKI therapy have also been reported. Here, we have reviewed the recent clinical and preclinical developments related to novel 3G EGFR-TKIs, including osimertinib, rociletinib, olmutinib, EGF816, and ASP8273.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

egfr, patients, google, scholar, cancer, article, pubmed, resistance, study, lung, osimertinib, nsclc, therapy, phase, rociletinib, cas, cell, acquired, clinical, egfrtkis, mutation, inhibitor, kinase, nct, studies, clinicaltrialsgov, advanced, treatment, oncol, mechanisms, mutationpositive, developed, mgday, central, nonsmall, tumor, plasma, growth, receptor, firstline, aes, factor, inhibitors, egfrtki, azd, tyrosine, tmpositive, mutations, yang, observed,

Topics {✒️}

/press-release/boehringer-ingelheim-launches-ambitious-eluxa-trial-programme james chih-hsin yang methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1 anti-pd-l1 monoclonal antibody quinazoline-based 1g/2g egfr-tkis 1g/2g egfr-tki therapy egfr mutant-specific inhibitor mutant-specific egfr inhibitor mutant-selective allosteric inhibitors t790m-specific egfr inhibitor anti-pd-1 monoclonal antibody small-cell lung cancer small-cell lung cancer cell-free plasma dna lymphoid tyrosine kinase egfr-mutant lung cancer mutant-selective covalent inhibitor egfr-mutant lung cancers advanced egfr mutation-positive irreversible kinase inhibitor 1-methyl-1h-pyrazol-4-yl t790m-positive advanced nsclc targeting high-level met-amplification egfr mutation-positive nsclc egfr l858r/t790m/c797s structure-based design approach safety profile prior egfr-tki therapy egfr t790m-positive plasma irreversible egfr-tki afatinib article download pdf 1/2g egfr-tki therapy mono-anilino-pyrimidine compound 1g/2g egfr-tkis 3g egfr-tki aim manual search m1a/m0 intrathoracic disease inhibit wild-type egfr growth factor 1 3g egfr-tki therapy overcomes t790m-mediated resistance chia-chi lin 1g/3g egfr-tkis median progression-free survival egfr t790m-positive tissue 1/2g egfr-tki treatment chung-shan south road national taiwan university stage iiib/iv patients line egfr-tki therapy

Questions {❓}

Zhtml?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
         description:The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (1/2G EGFR-TKIs) gefitinib, erlotinib, and afatinib have all been approved as standard first-line treatments for advanced EGFR mutation-positive non-small cell lung cancer. The third-generation (3G) EGFR-TKIs have been developed to overcome the EGFR T790M mutation, which is the most common mechanism of acquired resistance to 1/2G EGFR-TKI treatment. This resistance mutation develops in half of the patients who respond to 1/2G EGFR-TKI therapy. The structures of the novel 3G EGFR-TKIs are different from those of 1/2G EGFR-TKIs. Particularly, 3G EGFR-TKIs have lower affinity to wild-type EGFR, and are therefore associated with lower rates of skin and gastrointestinal toxicities. However, many of the adverse events (AEs) that are observed in patients receiving 3G EGFR-TKIs have not been observed in patients receiving 1/2G EGFR-TKIs. Although preclinical studies have revealed many possible mechanisms for these AEs, the causes of some AEs remain unknown. Many mechanisms of resistance to 3G EGFR-TKI therapy have also been reported. Here, we have reviewed the recent clinical and preclinical developments related to novel 3G EGFR-TKIs, including osimertinib, rociletinib, olmutinib, EGF816, and ASP8273.
         datePublished:2016-12-03T00:00:00Z
         dateModified:2016-12-03T00:00:00Z
         pageStart:1
         pageEnd:10
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12929-016-0305-9
         keywords:
            Non-small cell lung cancer
            Epidermal growth factor receptor
            Tyrosine kinase inhibitor
            T790M mutation
            Osimertinib
            Rociletinib
            Olmutinib
            EGF816
            ASP8273
            Biomedicine
            general
         image:
         isPartOf:
            name:Journal of Biomedical Science
            issn:
               1423-0127
            volumeNumber:23
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Bin-Chi Liao
               affiliation:
                     name:National Taiwan University Hospital
                     address:
                        name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
                     name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University
                     address:
                        name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
                     name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University
                     address:
                        name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chia-Chi Lin
               affiliation:
                     name:National Taiwan University Hospital
                     address:
                        name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
                     name:College of Medicine, National Taiwan University
                     address:
                        name:Department of Urology, College of Medicine, National Taiwan University, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jih-Hsiang Lee
               affiliation:
                     name:National Taiwan University Hospital
                     address:
                        name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
                     name:National Taiwan University Hospital
                     address:
                        name:Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:James Chih-Hsin Yang
               affiliation:
                     name:National Taiwan University Hospital
                     address:
                        name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
                     name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University
                     address:
                        name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
                     name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University
                     address:
                        name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
                     name:Graduate Institute of Oncology, College of Medicine, National Taiwan University
                     address:
                        name:Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
      description:The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (1/2G EGFR-TKIs) gefitinib, erlotinib, and afatinib have all been approved as standard first-line treatments for advanced EGFR mutation-positive non-small cell lung cancer. The third-generation (3G) EGFR-TKIs have been developed to overcome the EGFR T790M mutation, which is the most common mechanism of acquired resistance to 1/2G EGFR-TKI treatment. This resistance mutation develops in half of the patients who respond to 1/2G EGFR-TKI therapy. The structures of the novel 3G EGFR-TKIs are different from those of 1/2G EGFR-TKIs. Particularly, 3G EGFR-TKIs have lower affinity to wild-type EGFR, and are therefore associated with lower rates of skin and gastrointestinal toxicities. However, many of the adverse events (AEs) that are observed in patients receiving 3G EGFR-TKIs have not been observed in patients receiving 1/2G EGFR-TKIs. Although preclinical studies have revealed many possible mechanisms for these AEs, the causes of some AEs remain unknown. Many mechanisms of resistance to 3G EGFR-TKI therapy have also been reported. Here, we have reviewed the recent clinical and preclinical developments related to novel 3G EGFR-TKIs, including osimertinib, rociletinib, olmutinib, EGF816, and ASP8273.
      datePublished:2016-12-03T00:00:00Z
      dateModified:2016-12-03T00:00:00Z
      pageStart:1
      pageEnd:10
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12929-016-0305-9
      keywords:
         Non-small cell lung cancer
         Epidermal growth factor receptor
         Tyrosine kinase inhibitor
         T790M mutation
         Osimertinib
         Rociletinib
         Olmutinib
         EGF816
         ASP8273
         Biomedicine
         general
      image:
      isPartOf:
         name:Journal of Biomedical Science
         issn:
            1423-0127
         volumeNumber:23
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Bin-Chi Liao
            affiliation:
                  name:National Taiwan University Hospital
                  address:
                     name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
                  name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University
                  address:
                     name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
                  name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University
                  address:
                     name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chia-Chi Lin
            affiliation:
                  name:National Taiwan University Hospital
                  address:
                     name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
                  name:College of Medicine, National Taiwan University
                  address:
                     name:Department of Urology, College of Medicine, National Taiwan University, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jih-Hsiang Lee
            affiliation:
                  name:National Taiwan University Hospital
                  address:
                     name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
                  name:National Taiwan University Hospital
                  address:
                     name:Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:James Chih-Hsin Yang
            affiliation:
                  name:National Taiwan University Hospital
                  address:
                     name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
                  name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University
                  address:
                     name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
                  name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University
                  address:
                     name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
                  name:Graduate Institute of Oncology, College of Medicine, National Taiwan University
                  address:
                     name:Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Biomedical Science
      issn:
         1423-0127
      volumeNumber:23
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:National Taiwan University Hospital
      address:
         name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
         type:PostalAddress
      name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University
      address:
         name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University, Taipei, Taiwan
         type:PostalAddress
      name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University
      address:
         name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
         type:PostalAddress
      name:National Taiwan University Hospital
      address:
         name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
         type:PostalAddress
      name:College of Medicine, National Taiwan University
      address:
         name:Department of Urology, College of Medicine, National Taiwan University, Taipei, Taiwan
         type:PostalAddress
      name:National Taiwan University Hospital
      address:
         name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
         type:PostalAddress
      name:National Taiwan University Hospital
      address:
         name:Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan
         type:PostalAddress
      name:National Taiwan University Hospital
      address:
         name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
         type:PostalAddress
      name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University
      address:
         name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University, Taipei, Taiwan
         type:PostalAddress
      name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University
      address:
         name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
         type:PostalAddress
      name:Graduate Institute of Oncology, College of Medicine, National Taiwan University
      address:
         name:Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Bin-Chi Liao
      affiliation:
            name:National Taiwan University Hospital
            address:
               name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
               type:PostalAddress
            type:Organization
            name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University
            address:
               name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University, Taipei, Taiwan
               type:PostalAddress
            type:Organization
            name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University
            address:
               name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
               type:PostalAddress
            type:Organization
      name:Chia-Chi Lin
      affiliation:
            name:National Taiwan University Hospital
            address:
               name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
               type:PostalAddress
            type:Organization
            name:College of Medicine, National Taiwan University
            address:
               name:Department of Urology, College of Medicine, National Taiwan University, Taipei, Taiwan
               type:PostalAddress
            type:Organization
      name:Jih-Hsiang Lee
      affiliation:
            name:National Taiwan University Hospital
            address:
               name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
               type:PostalAddress
            type:Organization
            name:National Taiwan University Hospital
            address:
               name:Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan
               type:PostalAddress
            type:Organization
      name:James Chih-Hsin Yang
      affiliation:
            name:National Taiwan University Hospital
            address:
               name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
               type:PostalAddress
            type:Organization
            name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University
            address:
               name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University, Taipei, Taiwan
               type:PostalAddress
            type:Organization
            name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University
            address:
               name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
               type:PostalAddress
            type:Organization
            name:Graduate Institute of Oncology, College of Medicine, National Taiwan University
            address:
               name:Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
      name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University, Taipei, Taiwan
      name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
      name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
      name:Department of Urology, College of Medicine, National Taiwan University, Taipei, Taiwan
      name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
      name:Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan
      name:Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
      name:National Taiwan University Cancer Center, College of Medicine, National Taiwan University, Taipei, Taiwan
      name:Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
      name:Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan

External Links {🔗}(262)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.93s.

LINK . SPRINGER . COM {}